JP2021527656A5 - - Google Patents
Info
- Publication number
- JP2021527656A5 JP2021527656A5 JP2020570444A JP2020570444A JP2021527656A5 JP 2021527656 A5 JP2021527656 A5 JP 2021527656A5 JP 2020570444 A JP2020570444 A JP 2020570444A JP 2020570444 A JP2020570444 A JP 2020570444A JP 2021527656 A5 JP2021527656 A5 JP 2021527656A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- identity
- progranulin
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862686579P | 2018-06-18 | 2018-06-18 | |
| US62/686,579 | 2018-06-18 | ||
| US201862746338P | 2018-10-16 | 2018-10-16 | |
| US62/746,338 | 2018-10-16 | ||
| PCT/US2019/037695 WO2019246071A1 (en) | 2018-06-18 | 2019-06-18 | Fusion proteins comprising progranulin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527656A JP2021527656A (ja) | 2021-10-14 |
| JP2021527656A5 true JP2021527656A5 (cg-RX-API-DMAC7.html) | 2022-06-27 |
| JP7517997B2 JP7517997B2 (ja) | 2024-07-17 |
Family
ID=67138158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570444A Active JP7517997B2 (ja) | 2018-06-18 | 2019-06-18 | プログラニュリンを含む融合タンパク質 |
Country Status (17)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3991748A3 (en) | 2015-04-07 | 2022-08-24 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| AU2016270587B2 (en) * | 2015-05-29 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a disruption in a C9ORF72 locus |
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| SMT202300110T1 (it) | 2018-07-13 | 2023-05-12 | Alector Llc | Anticorpi anti-sortilina e relativi metodi di uso |
| CA3109763A1 (en) * | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| US20210396772A1 (en) * | 2018-10-16 | 2021-12-23 | Denali Therapeutics Inc. | Methods for treating and monitoring progranulin-associated disorders |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| AU2020252554B2 (en) | 2019-04-03 | 2026-05-28 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
| BR112022012230A2 (pt) * | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| CN116133684B (zh) * | 2020-05-27 | 2025-07-18 | 阿里亚利斯治疗公司 | 抗人nr1抗体衍生物 |
| US20210393787A1 (en) * | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| KR102666958B1 (ko) * | 2020-09-18 | 2024-05-23 | 한양대학교 산학협력단 | PTPsigma-Fc 융합단백질 및 이를 포함하는 약학 조성물 |
| EP4215607A4 (en) * | 2020-09-18 | 2024-11-06 | IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) | Ptpsigma-fc fusion protein and pharmaceutical composition comprising same |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| EP4229419A2 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Methods for treating and monitoring frontotemporal dementia |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| AR128003A1 (es) * | 2021-12-17 | 2024-03-20 | Denali Therapeutics Inc | PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS |
| WO2023198661A1 (en) * | 2022-04-12 | 2023-10-19 | F. Hoffmann-La Roche Ag | Fusion proteins targeted to the central nervous system |
| CN119213030A (zh) * | 2022-05-16 | 2024-12-27 | 戴纳立制药公司 | 转铁蛋白受体结合结构域和包含其的蛋白 |
| JP2024037109A (ja) * | 2022-09-06 | 2024-03-18 | 国立大学法人九州大学 | 分析容器、前処理方法、代謝物解析方法、タンパク質解析方法、及び質量分析方法 |
| EP4630030A2 (en) * | 2022-12-06 | 2025-10-15 | ProteinQure Inc. | Targeting sortilin |
| EP4731669A2 (en) * | 2023-06-21 | 2026-04-29 | Eli Lilly and Company | Compounds for the delivery of granulin across the blood brain barrier |
| WO2025051953A1 (en) * | 2023-09-07 | 2025-03-13 | Novo Nordisk A/S | Sortilin-1 binders, constructs and uses thereof |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
| WO2025166077A1 (en) * | 2024-01-31 | 2025-08-07 | Alector Llc | Compositions comprising progranulin and uses thereof |
| EP4755905A1 (en) | 2024-12-05 | 2026-06-10 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Truncated progranulin protein and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010022175A1 (en) * | 2008-08-19 | 2010-02-25 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| EP3991748A3 (en) * | 2015-04-07 | 2022-08-24 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| AU2016282334B2 (en) * | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| WO2018024162A1 (en) * | 2016-08-03 | 2018-02-08 | Sunshine Lake Pharma Co., Ltd. | Glp-1 fusion protein comprising mutated immunoglobulin fc portion |
| EP4628586A3 (en) | 2017-02-17 | 2026-01-14 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
-
2019
- 2019-06-18 WO PCT/US2019/037695 patent/WO2019246071A1/en not_active Ceased
- 2019-06-18 US US17/253,391 patent/US20210284702A1/en not_active Abandoned
- 2019-06-18 KR KR1020217001552A patent/KR20210027377A/ko not_active Ceased
- 2019-06-18 BR BR112020025306-5A patent/BR112020025306A2/pt unknown
- 2019-06-18 EP EP19735097.8A patent/EP3807322A1/en active Pending
- 2019-06-18 PE PE2020002083A patent/PE20210323A1/es unknown
- 2019-06-18 CN CN201980039158.0A patent/CN112424233A/zh active Pending
- 2019-06-18 CA CA3101202A patent/CA3101202A1/en active Pending
- 2019-06-18 AU AU2019288212A patent/AU2019288212B2/en active Active
- 2019-06-18 MX MX2020012518A patent/MX2020012518A/es unknown
- 2019-06-18 TW TW108121124A patent/TWI874321B/zh active
- 2019-06-18 IL IL279510A patent/IL279510B2/en unknown
- 2019-06-18 JP JP2020570444A patent/JP7517997B2/ja active Active
- 2019-06-18 SG SG11202011743SA patent/SG11202011743SA/en unknown
-
2020
- 2020-12-11 PH PH12020552189A patent/PH12020552189A1/en unknown
- 2020-12-16 CL CL2020003255A patent/CL2020003255A1/es unknown
- 2020-12-16 EC ECSENADI202081591A patent/ECSP20081591A/es unknown
-
2023
- 2023-04-12 US US18/299,458 patent/US20230406898A1/en not_active Abandoned
-
2025
- 2025-02-04 US US19/044,856 patent/US20260001925A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7397063B2 (ja) | 操作された二重特異性タンパク質 | |
| KR102514330B1 (ko) | Pd-1 및 lag-3와의 면역반응성을 가진 공유 결합된 디아바디, 및 그것의 사용 방법 | |
| JP6744856B2 (ja) | α−シヌクレインを認識する抗体を含む血液脳関門シャトル | |
| ES2749457T3 (es) | Anticuerpos humanizados que reconocen la alfa-sinucleína | |
| JP2023512450A5 (cg-RX-API-DMAC7.html) | ||
| JP2021533779A5 (cg-RX-API-DMAC7.html) | ||
| KR20190134997A (ko) | 항-tau 항체 및 이의 사용 방법 | |
| EP2985294A1 (en) | Recombinant antibody molecule and its use for target cell restricted T cell activation | |
| JP2021534220A5 (cg-RX-API-DMAC7.html) | ||
| KR102884943B1 (ko) | 개선된 항-flt3 항원 결합 단백질 | |
| US20210070881A1 (en) | Anti-bace1 antibodies and methods of use thereof | |
| CN109963869A (zh) | 与经改造的Fc构建体相关的组合物和方法 | |
| US12473369B2 (en) | Fusion protein of anti-eta antibody and tgf-beta trap and pharmaceutical composition and application thereof in method of treatment | |
| JP2023545707A5 (cg-RX-API-DMAC7.html) | ||
| US20240279324A1 (en) | Multispecific antagonists | |
| JP2022530068A5 (cg-RX-API-DMAC7.html) | ||
| TH2001007134A (th) | ฟิวชันโปรตีนซึ่งประกอบรวมด้วยโพรแกรนูลิน | |
| KR20230123923A (ko) | 항-EphA4 항체 | |
| JP2021510162A5 (cg-RX-API-DMAC7.html) | ||
| CA3111462C (en) | Improved anti-flt3 antigen binding proteins | |
| US20230391880A1 (en) | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof | |
| KR20230118573A (ko) | 액티빈/tgf-베타 및 rankl의 이작용성 길항제 및 이의 용도 |